Quantcast

Latest Pulmonology Stories

2014-05-01 23:15:53

With allergy season in full swing, medical professionals are hearing more complaints about congestion and trouble breathing. In addition to medications and lifestyle changes, the Pulmonica can help patients improve their breathing. Sarasota, FL (PRWEB) May 01, 2014 “The Pulmonica was developed to help my brother-in-law who had emphysema, and has been used successfully by patients with COPD, asthma, and allergies,” said Dana Keller, PhD, co-inventor of the pulmonary harmonica. “The...

2014-05-01 12:28:46

Reduction in Exacerbations Remains the Top Driver of Physician Prescribing Choice in Moderate to Severe Asthma, According to Findings from Decision Resources Group BURLINGTON, Mass., May 1, 2014 /PRNewswire/ -- Decision Resources Group finds that 90 percent of surveyed U.S. payers indicated a willingness to pay a premium-price for a novel therapy with substantially greater improvements in reducing exacerbations than Genentech/Novartis's Xolair in the treatment of severe asthma. Surveyed U.S....

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK's first once-daily anticholinergic, a type of...

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...

2014-04-30 11:11:48

Specificity double that of PET scans, according to presentation at 94th AATS Annual Meeting Researchers at the University of Louisville School of Medicine are using breath analysis to detect the presence of lung cancer. Preliminary data indicate that this promising noninvasive tool offers the sensitivity of PET scanning, and has almost twice the specificity of PET for distinguishing patients with benign lung disease from those with early stage cancer. Michael Bousamra II, MD, Associate...

2014-04-30 08:34:06

Parion plans to initiate Phase 2 studies of P-1037 for the treatment of cystic fibrosis in the second half of 2014 DURHAM, N.C., April 30, 2014 /PRNewswire/ -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it has reached an agreement with Gilead Sciences, Inc. to reacquire the rights to epithelial sodium channel (ENaC) inhibitors identified and developed under a research collaboration announced...

2014-04-28 08:32:52

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro(TM) Ellipta(®) (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies...

2014-04-24 12:28:48

Each of the Emerging LABA/LAMA Fixed-Dose Combinations Has Advantages Over Current Therapies on Efficacy Measures, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European pulmonologists agree that a therapy offering a greater reduction in exacerbations is among the areas of greatest opportunity for chronic obstructive pulmonary disease (COPD) treatments. The majority of surveyed U.S....

2014-04-23 23:04:20

New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com. According to the study, the world COPD market is predicted to grow at a CAGR of nearly 8% and reach USD 17.5 billion by 2018. London, UK (PRWEB) April 23, 2014 Around 1 billion people across the globe suffer from pulmonary or respiratory diseases. Within the respiratory therapeutic domain, chronic obstructive pulmonary disease...

2014-04-21 00:20:49

SAN DIEGO, April 21, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). Our results indicate that very small inhaled doses deliver oral-superior, but short-lived lung levels. To understand if this increased lung dose may...


Latest Pulmonology Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »
Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related